Dr. Lal Path Labs earnings calls.

Dr. Lal PathLabs delivered a strong Q1 FY27 with 19.1% revenue growthCurrent reported value: 19.1% revenue growth. No comparable prior figure is available in the source record. (highest quarterly growth in 4 years) driven by 8.2% patient volume growth and favorable CGHS/ECHS price increases contributing 2-3% to realizations. EBITDA margin expanded to 31%Current 31% vs previous available quarter 27.2%. (+220bps YoY) reflecting operational leverage, though management indicated intent to reinvest incremental profits into growth initiatives. Test per patient improved to 3.14Current 3.14. Reported change: +0.07 YoY. from 3.07, signaling better wallet share capture. The 116 new tests launched (4 first-in-India) and GenAI patient engagement tools on WhatsApp position the company well for specialized testing growth. B2C mix held steady at 75%Current 75%. Reported change: Flat YoY., while Suburban (West India) business has turned around to near double-digit growth post-integration. For the full year, management guided towards mid-teens revenue growth and 27-28% EBITDA margins, with capex guidance of ₹140-150 crore for 12-15 lab additions and 3-4 radiology center expansions. Key risks include geopolitical pressures on imported reagents and seasonal volume volatility given Q1's unusual weather patterns.